Annexon Inc (NAS:ANNX)
$ 5.39 0.05 (0.94%) Market Cap: 574.54 Mil Enterprise Value: 264.03 Mil PE Ratio: 0 PB Ratio: 1.72 GF Score: 40/100

Annexon Inc GA Update Call Transcript

May 24, 2023 / 08:30PM GMT
Release Date Price: $5.17 (-7.84%)
Operator

Hello and welcome to Annexon's conference call. (Operator Instructions) Please be advised that this call is being recorded at Annexon's request. I would now like to turn the call over to Lori Murray, Senior Vice President, Investor Relations and Corporate Communications. You may begin.

Lori Murray
Annexon, Inc. - SVP, IR & Corporate Communications

Thank you, Jonathan, and good afternoon. Earlier today we issued a press release outlining topline data from our ARCHER Phase 2 clinical trial evaluating ANX007 in patients with geographic atrophy.

The press release and the slides to which we'll refer are available under the Events and Presentations page within the Investors section of our website.

On the call with me today is our CEO, Douglas Love; as well as our Chief Innovation Officer, Dr. Ted Yednock; and our VP and Head of ophthalmology, Dr. Donald Fong. In addition, we are delighted to have Dr. Charles Wykoff join us for the Q&A session. Dr. Wykoff is the Director of Research at the Retina Consultants of Texas and an investigator in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot